Navigation Links
Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Date:7/7/2011

ctions and infestations, which were observed in 72% of patients on everolimus and 67% of patients on placebo(1).

EXIST-1 enrolled 117 patients in 10 countries, including the US, Poland, Russia, Germany, Belgium, Canada, Australia, Italy, the Netherlands and the UK(1,10).

About the Phase II studyIn this prospective, open-label, single-arm study, 28 patients aged three years and above (median age=11, range 3-34) with evidence of SEGA growth received a median daily dose of 5.29 mg/m2. The median treatment duration was 34.2 months (range 4.7-47.1 months). Of the 28 patients in the initial study, 27 were enrolled in the extension phase and 25 were still receiving everolimus at the extension phase cut-off date (December 31, 2010). No patients discontinued due to disease progression, adverse events or study drug use(5).

During this extension phase, reduction in SEGA volume was maintained over time and no patients required surgery or other therapy for SEGA or hydrocephalus. In the study, 78% of patients (7 of 9) who took everolimus for at least three years and 79% of patients (19 of 24) who took everolimus for at least two years experienced a reduction of 30% or greater in the size of their largest SEGA relative to baseline. Additionally, 56% of patients (5 of 9) who took everolimus for at least three years and 50% of patients (12 of 24) who took everolimus for at least two years experienced a reduction of 50% or greater in the size of their largest SEGA relative to baseline(5). These findings were consistent with those previously recorded at six months relative to baseline(2,5).

The most common AEs (all grades with an incidence of at least 20%) included: stomatitis or mouth sores (86%), upper respiratory tract infection (86%), sinusitis (47%), middle ear infection (36%), diarrhea (32%), fever (32%), cellulitis or acute infection of the deep tissues of skin or muscle (29%), convulsion (29%), gastroenteritis or inflammation of the gastrointest
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
2. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
3. Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal
4. Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
5. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
6. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
7. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
8. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
9. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
10. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
11. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... 12, 2014 Research and Markets ( ... "Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, ... http://photos.prnewswire.com/prnh/20130307/600769 Global Electrocardiogram Devices ... 2016. The North America accounts ... while Europe claims approximately 27% ...
(Date:12/15/2014)... 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... to the NASDAQ Biotechnology Index (NBI). The addition ... upon market open on December 22, 2014. ... track the performance of a set of NASDAQ-listed ... pharmaceutical according to the Industry Classification Benchmark. The ...
(Date:12/15/2014)... , Dec. 15, 2014  Stephen Squires, CEO and ... Quantum Materials Corp (OTCQB:QTMM), will be speaking at ... Materials (RCQM) on December 16th, 2014. The RCQM launch ... nanomaterials in attracting top faculty and students and by ... on research. "We have a long ...
Breaking Medicine Technology:Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 2Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 3
(Date:12/17/2014)... 17, 2014 Now in its second ... best of the best in senior living and home ... given to communities and agencies that have received outstanding ... Of the nearly 100,000 providers currently listed on SeniorAdvisor.com, ... the SeniorAdvisor.com Best of 2015 Awards are located all ...
(Date:12/17/2014)... Alan Mozes HealthDay Reporter , ... of infectious diseases, one worrisome phenomenon is when an illness ... process -- known as zoonosis -- is not uncommon and ... that an animal-borne disease might make inroads into the human ... development -- and the culprits in this case were guinea ...
(Date:12/17/2014)... Dec. 16, 2014 (HealthDay News) -- Greater participation in ... study finds. Researchers followed kids in the nonprofit ... poor children in Los Angeles. Over two years, ... improvements in how the brain processes speech and reading, ... Also, the benefits of active participation in music classes ...
(Date:12/17/2014)... Kathleen Doheny HealthDay Reporter ... sleep loss is rampant in America, and work commitment is ... the No. 1 sleep killer," said Dr. Mathias Basner, an ... University of Pennsylvania Perelman School of Medicine. A time-use ... found that work is the main activity exchanged for sleep. ...
(Date:12/15/2014)... 15, 2014 Veretekk.com, Inc. announced today ... Avenue. JM Ocean Avenue has secured exclusive benefit ... automated marketing system. JM Ocean Avenue is a ... of Ocean Avenue and JM International, with partial ownership ... per year company. , “After nearly 2 decades of ...
Breaking Medicine News(10 mins):Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 3Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3Health News:Music Classes Boost Language Skills, Study Says 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4
... Million in Net Cash Proceeds from Private Placement ... of Debt into Equity, CEDAR KNOLLS, N.J., ... MDFI), a company specializing in,portable electronic medical records ... net proceeds of $1.95 million from three,separate private ...
... for a Cause To Support Stefanie LaRue and Her ... year old,breast cancer survivor Stefanie LaRue, known nationally as ... diagnosed with breast,cancer, is being honored at a benefit ... Center, located at 2701 N. Sepulveda Blvd., Los,Angeles, CA. ...
... MERCERVILLE, N.J., Jan. 29 Laser Energetics,Inc. (Pink ... an order for,a fully developed, pre-production clinical laser ... system is based on Laser Energetics, proprietary and,patent ... placed by Hygenilase, Inc. Hygenilase is a newly-formed,joint ...
... FairWarning(R) name, company introduces new out-of-the-box proactive, ... needs, ST. PETERSBURG, Fla., Jan. 29 ... to FairWarning(R). The company,s corporate,structure and mission remains ... leading supplier of cross-platform privacy auditing,solutions for Electronic ...
... ... represents an increase of 15% reported (10% constant currency), ... -- Diluted EPS were $1.12 reported, an increase of 10% over the prior ... the prior year period, Zimmer Holdings, Inc. (NYSE: ...
... Overall Health Affects Their ... Recovery From Schizophrenia, WASHINGTON, Jan. 29 ... to examine overall,healthcare in mental health settings from the perspective of ... aware of actions to improve overall health and quality of life,they ...
Cached Medicine News:Health News:MedeFile Materially Strengthens Balance Sheet Through Equity Financing and Debt Conversion Totaling $4 Million 2Health News:MedeFile Materially Strengthens Balance Sheet Through Equity Financing and Debt Conversion Totaling $4 Million 3Health News:MedeFile Materially Strengthens Balance Sheet Through Equity Financing and Debt Conversion Totaling $4 Million 4Health News:32-Year-Old Breast Cancer Survivor, Fashion Model Featured in Benefit Concert 'Music of the Light' at Skirball Cultural Center 2Health News:32-Year-Old Breast Cancer Survivor, Fashion Model Featured in Benefit Concert 'Music of the Light' at Skirball Cultural Center 3Health News:Laser Energetics Receives a $550,000 Order for a Dental Laser System 2Health News:Laser Energetics Receives a $550,000 Order for a Dental Laser System 3Health News:EpicTide Changes Name to FairWarning(R) 2Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 2Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 3Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 4Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 5Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 6Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 7Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 8Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 9Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 10Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 11Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 12Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 13Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 14Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 15Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 16Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 17Health News:First-of-Its-Kind National Survey Uncovers Obstacles to Comprehensive Healthcare for People With Schizophrenia 2Health News:First-of-Its-Kind National Survey Uncovers Obstacles to Comprehensive Healthcare for People With Schizophrenia 3Health News:First-of-Its-Kind National Survey Uncovers Obstacles to Comprehensive Healthcare for People With Schizophrenia 4
... model CC4204BF, is a single ... the capsular bag. The lens ... post-operative fixation. The light patterns ... are nearly identical to those ...
The STAAR ELASTIMIDE™ lens, combines the best of foldable lens technology with traditional design. This lens contains a cast-molded, silicone optic with modified Polyimide haptics....
... at Pfizer used wavefront sensing to invent ... Innovative TECNIS features a patented modified prolate ... which compensates for the positive spherical aberration ... is the first and only IOL with ...
Multi piece lens, AC depth: 4.2....
Medicine Products: